Intercept Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Update
May 04, 2017 11:05 am UTC| Business
Worldwide net Ocaliva® (obeticholic acid or OCA) 1Q 2017 sales of $20.6 millionCompleted enrollment of Phase 3 REGENERATE trial interim analysis cohort: data expected in 1H 2019 Conference call scheduled for 8:30 a.m. ET...
May 04, 2017 11:04 am UTC| Business
KNOXVILLE, Tenn., May 04, 2017 -- Scripps Networks Interactive (Nasdaq:SNI) today announced a new deal with Snap Inc. that will bring new food- and home-related programming, including Shows, to Snapchat’s Discover...
Keryx Biopharmaceuticals Announces First Quarter 2017 Financial Results
May 04, 2017 11:03 am UTC| Business
Company reported $11.8 million in first quarter 2017 total revenue, including net U.S. Auryxia® (ferric citrate) product sales of $10.5 million Provides 2017 net U.S. Auryxia product sales guidance of $56 to $60...
Abiomed Announces First Patient Enrolled in STEMI DTU Feasibility Study
May 04, 2017 11:03 am UTC| Business
DANVERS, Mass., May 04, 2017 -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, announced today the enrollment of the first patient in the Food and Drug Administration (FDA)...
Abiomed Announces First Patient Enrolled in STEMI DTU Feasibility Study
May 04, 2017 11:03 am UTC| Business
DANVERS, Mass., May 04, 2017 -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, announced today the enrollment of the first patient in the Food and Drug Administration (FDA)...
Agios Reports First Quarter 2017 Financial Results
May 04, 2017 11:03 am UTC| Business
– IDHIFA® (enasidenib) Granted Priority Review by FDA with August 30, 2017 PDUFA Date; Updated Data from Phase 1/2 Trial in IDH2m R/R AML to be Presented at ASCO – – Ivosidenib Phase 1 125-Patient Expansion Cohort in...
Agios Reports First Quarter 2017 Financial Results
May 04, 2017 11:03 am UTC| Business
– IDHIFA® (enasidenib) Granted Priority Review by FDA with August 30, 2017 PDUFA Date; Updated Data from Phase 1/2 Trial in IDH2m R/R AML to be Presented at ASCO – – Ivosidenib Phase 1 125-Patient Expansion Cohort in...
Threading Opportunity: How an India–EU FTA Could Reweave Textile Fortunes